GSK3β-Mediated Expression of CUG-Translated WT1 Is Critical for Tumor Progression.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33184107.
- Also identified by DOI 10.1158/0008-5472.CAN-20-1880.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The <i>Wilms' tumor 1</i> (<i>WT1</i>) gene is well known as a chameleon gene. It plays a role as a tumor suppressor in Wilms' tumor but also acts as an oncogene in other cancers. Previously, our group reported that a canonical AUG starting site for the WT1 protein (augWT1) acts as a tumor suppressor, whereas a CUG starting site for the WT1 protein (cugWT1) functions as an oncogene. In this study, we report an oncogenic role of cugWT1 in the AOM/DSS-induced colon cancer mouse model and in a urethane-induced lung cancer model in mice lacking cugWT1. Development of chemically-induced tumors was significantly depressed in cugWT1-deficient mice. Moreover, glycogen synthase kinase 3β promoted phosphorylation of cugWT1 at S64, resulting in ubiquitination and degradation of the cugWT1 associated with the F-box<sup>-/-</sup> WD repeat-containing protein 8. Overall, our findings suggest that inhibition of cugWT1 expression provides a potential candidate target for therapy. SIGNIFICANCE: These findings demonstrate that CUG-translated WT1 plays an oncogenic role <i>in vivo</i>, and GSK3β-mediated phosphorylation of cugWT1 induces its ubiquitination and degradation in concert with FBXW8.
Medical subject headings
- Glycogen Synthase Kinase 3 beta
- Kidney Neoplasms
- WT1 Proteins
- Wilms Tumor